|
|
|
|
|
|
|
EXPERT-LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
|
Sustained Benefit to Metastasis-Directed Therapy Versus Observation: A Pooled Analysis of the STOMP and ORIOLE Trials Journal Club
|
Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Journal of Clinical Oncology publication titled, "Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials".
|
|
|
|
|
|
|
|
|
| Improvement in rPFS with Abiraterone Plus Olaparib Over Abiraterone Plus Placebo in First-Line mCRPC Irrespective of HRR Mutation Status, The PROpel Trial Journal Club
|
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the PROpel study and the New England Journal of Medicine Evidence publication titled, "Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer".
|
|
|
|
|
|
|
|
|
|
|
| 223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club
|
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication titled, "Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study".
|
|
|
|
|
|
| Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club
|
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen focus this discussion on the article published in The Lancet titled "Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound)."
|
|
|
|
|
|
|
|
|
|
|
|
